Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced a $300,000 G-Rex Grant awarded to the Gates Institute for developing a modular CAR T-cell manufacturing platform [1][2]. Funding and Support - The G-Rex Grant will facilitate the development of efficient manufacturing approaches for cell and gene therapy programs, optimizing space, capital, and personnel while ensuring cell health and quality [2]. - ScaleReady's G-Rex Grant Program has authorized over $40 million in products at no cost to grant recipients, with individual awards up to $300,000 [5]. Research and Development - The grant will support a structured Design of Experiments (DoE) to optimize CAR-T cell manufacturing steps by evaluating critical variables [3]. - Gates Institute will gain early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation designed for high-throughput, low-cost manufacturing [4]. Industry Impact - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, as well as 5 commercially approved CGT drugs [8]. - ScaleReady's expertise is expected to save years and millions of dollars for CGT entities on the path to commercialization [9]. Collaborative Initiatives - ScaleReady has launched a free program called LEAN Cell & GeneTM in partnership with Hanson Wade, aimed at helping CGT entities identify and eliminate waste while improving drug product quality [6].